Abstract
Myelofibrosis (MF) is a heterogeneous disease for which long-term, effective medical therapeutic options are currently limited. The role of allogeneic haematopoietic stem cell transplant (AHSCT) in this population, many of whom are elderly, often provides a challenge with regard to the identification of suitable candidates, timing of transplantation in the disease course and choice of conditioning regimen. This review summarizes key findings from published data concerning AHSCT in MF and attempts to provide a state of the art approach to MF-AHSCT in 2012. In addition, we postulate on how the era of JAK inhibition might impact on transplantation for MF.
Original language | English |
---|---|
Pages (from-to) | 413-425 |
Number of pages | 13 |
Journal | British Journal of Haematology |
Volume | 157 |
Issue number | 4 |
DOIs | |
Publication status | Published - May 2012 |
Keywords
- myelofibrosis
- stem cell transplant
- splenectomy
- JAK inhibitors
- VERSUS-HOST-DISEASE
- INTERNATIONAL WORKING GROUP
- AGNOGENIC MYELOID METAPLASIA
- CORD BLOOD TRANSPLANTATION
- PROGNOSTIC SCORING SYSTEM
- DONOR-LYMPHOCYTE INFUSION
- REAL-TIME PCR
- POLYCYTHEMIA-VERA
- ESSENTIAL THROMBOCYTHEMIA
- IDIOPATHIC MYELOFIBROSIS